Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PLSE 
Pulse Biosciences Inc (PLSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: PLSE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -6.13% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) - | Beta 1.63 | 52 Weeks Range 10.52 - 25.00 | Updated Date 06/29/2025 |
52 Weeks Range 10.52 - 25.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.61% | Return on Equity (TTM) -77.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 903787838 | Price to Sales(TTM) 60.23 |
Enterprise Value 903787838 | Price to Sales(TTM) 60.23 | ||
Enterprise Value to Revenue 64.63 | Enterprise Value to EBITDA -1.81 | Shares Outstanding 67273904 | Shares Floating 17434021 |
Shares Outstanding 67273904 | Shares Floating 17434021 | ||
Percent Insiders 74 | Percent Institutions 8.64 |
Upturn AI SWOT
Pulse Biosciences Inc
Company Overview
History and Background
Pulse Biosciences, Inc. was founded in 2008. It is a bioelectric medicine company focused on developing and commercializing its proprietary Nano-Pulse Stimulation (NPS) technology platform.
Core Business Areas
- Dermatology: The company is focused on using its NPS technology for dermatological procedures, including the treatment of skin lesions.
- Veterinary Medicine: Applications in the veterinary field, including veterinary surgery.
- Research: Continue to develop and research other fields of applications of the NPS technology
Leadership and Structure
Kevin Danahy is the President and CEO. The company has a board of directors overseeing its strategic direction. It's a publicly traded company with a typical corporate structure.
Top Products and Market Share
Key Offerings
- CellFX System: The CellFX system is designed for dermatologic procedures. Pulse Biosciences is seeking clearance for other procedures. Market share data and revenue are not readily available. Competitors include companies with alternative aesthetic devices, such as lasers and radiofrequency devices, including Cutera (CUTR), Cynosure (CYNO) and Bausch Health (BHC).
Market Dynamics
Industry Overview
The aesthetic dermatology market is growing due to increasing demand for non-invasive procedures. The veterinary market is growing as well.
Positioning
Pulse Biosciences is positioned as a bioelectric medicine company with a novel technology platform. Its competitive advantage lies in its proprietary NPS technology.
Total Addressable Market (TAM)
The total addressable market is estimated to be billions of dollars in aesthetic dermatology. Pulse Biosciences is positioned to capture a portion of this market.
Upturn SWOT Analysis
Strengths
- Proprietary NPS technology
- Potential for multiple applications
- Strong intellectual property portfolio
Weaknesses
- Limited commercialization to date
- Dependence on regulatory approvals
- Negative earnings
Opportunities
- Expansion into new dermatological applications
- Partnerships with other companies
- Expansion into the veterinary market
Threats
- Competition from established aesthetic device companies
- Regulatory hurdles
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- CUTR
- CYNO
- BHC
Competitive Landscape
Pulse Biosciences' advantages are its novel NPS technology. Disadvantages include its limited commercial presence and the presence of larger, more established competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth has been limited due to the early stage of commercialization. Revenues are still limited. R&D expenses are material.
Future Projections: Future growth depends on regulatory approvals and commercialization success. Analyst estimates vary.
Recent Initiatives: Recent initiatives include focusing on the CellFX system and seeking regulatory clearances.
Summary
Pulse Biosciences is a bioelectric medicine company with promising NPS technology but faces challenges in commercialization and regulatory approvals. The company's future depends on the successful market penetration of the CellFX system. Competition is intense, and the company's financial health requires careful monitoring. Future revenue depends on expansion into the veterinary market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, publicly available market research reports, analyst estimates.
Disclaimers:
The data provided is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data is approximate. Ratings are AI-generated and for reference only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulse Biosciences Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2016-05-18 | President, CEO, Principal Executive Officer, Principal Financial Officer & Co-Chairman of the Board Mr. Paul Arthur LaViolette | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 75 | Website https://www.pulsebiosciences.com |
Full time employees 75 | Website https://www.pulsebiosciences.com | ||
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.